A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70200 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Giovanna S Manzano und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Central Nervous System Diseases, Myelitis, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales.
Methods
Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers. Cases were analyzed by initial treatment. The primary outcome was T1 post‐contrast gadolinium enhancement resolution at 6 months post‐treatment. Secondary outcomes were changes in modified Rankin scale (mRS) and Expanded Disability Status Scale (EDSS) from nadir to final follow‐up.
Results
Two hundred two patients were identified (median diagnosis age: 47 years (IQR 39–55); male: female 1.3:1). Median nadir mRS and EDSS were 2 (IQR 2–3) and 4 (IQR 2.5–6). At initial treatment, 129 (63.9%) received prolonged corticosteroids ≥ 4 weeks (group A 1 ), 36 (17.8%) received corticosteroids < 4 weeks (B 1 ), 21 (10.4%) received corticosteroids plus sarcoidosis‐directed immunosuppressant (E), and 16 (7.9%) received corticosteroids plus non‐sarcoidosis‐directed agents (F). In 167 cases with sufficient imaging, there were no significant differences in contrast enhancement resolution at 6 months (A 1 27/106 (25.5%), B 1 9/28 (32.1%), E 5/19 (26.3%), F 5/14 (35.7%); Fisher's exact p = 0.76). There were no significant differences in changes in mRS or EDSS among treatment groups (Kruskal–Wallis p = 0.69 and 0.63, respectively) after median follow‐up of 46.5 months (IQR 18–91.3).
Interpretation
Different initial immunosuppression strategies did not correlate with MRI contrast enhancement resolution at 6 months or clinical scales (mRS, EDSS). However, conclusions are limited by retrospective design, imbalanced cohorts, and insensitivity of binary MRI outcomes and available clinical scales for treatment response in neurosarcoidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Ophthalmology, Massachusetts Eye & Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Giovanna S Manzano, Michael Levy, Carlos A Pardo, Joseph R Berger, Rohini D Samudralwar, Steven Richard Dunham
Zitieren
APA
Manzano, G. S., Balaban, D., Zhang, Y., Healy, B., Chwalisz, B. K., Levy, M., Venna, N., Stern, B. J., Pardo, C. A., Barreras, P., Rjeily, N. B., Flanagan, E. P., Redenbaugh, V., Aksamit, A. J., Hutto, S., Herman, M., El Sammak, S., Rodriguez, E. C., Snider, L., …, & Bhattacharyya, S. (2025). A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70200
Vancouver
Manzano GS, Balaban D, Zhang Y, Healy B, Chwalisz BK, Levy M, et al. A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70200
BibTeX
@article{Manzano2025,
author = {Manzano, Giovanna S and Balaban, Denis and Zhang, Yihan and Healy, Brian and Chwalisz, Bart K and Levy, Michael and Venna, Nagagopal and Stern, Barney J and Pardo, Carlos A and Barreras, Paula and Rjeily, Nicole Bou and Flanagan, Eoin P and Redenbaugh, Vyanka and Aksamit, Allen J and Hutto, Spencer and Herman, Max and El Sammak, Sally and Rodriguez, Elsa C and Snider, Laura and Rains, Hannah and Montalvo, Mayra and Rempe, Torge and Ramirez, Sergi Martinez and Horta, Lucas and Clardy, Stacey and Lord, Jennifer and Cho, Tracey A and Abdel Wahed, Lama and Berger, Joseph R and Samudralwar, Rohini D and Torres, Noellie Rivera and Clifford, David B and Dunham, Steven Richard and Majed, Masoud and Zabeti, Aram and Marcucci, Samuel and Mao-Draayer, Yang and Doty, Jon and Agyei, Paunel B and Bhattacharyya, Shamik},
title = {A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70200}
}
EUVIMED